🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Poland / NCT07752459
Starting soon Not applicable

Physiological Responses to Basketball-Specific Interval Exercise in Female Basketball Players

NCT07752459 · tracked via the Priya Life Science Poland tracker
Phase
Not applicable
Started
2026-09-20
Last updated
2026-08-12

Condition(s) studied

ExerciseFatigueSport Physiology

Investigational drug(s) / intervention(s)

Yo-Yo Intermittent Recovery Test Level 1 (Yo-Yo IR1)

Yo-Yo Intermittent Recovery Test Level 1 (Yo-Yo IR1): The intervention consists of the Yo-Yo Intermittent Recovery Test Level 1 (Yo-Yo IR1), a standardized maximal intermittent field exercise test designed to reproduce the physiological demands of intermittent team sports such as basketball. Participants perform repeated 20-meter shuttle runs at progressively increasing speeds, guided by audio signals, with 10-second active recovery periods between running bouts. The test continues until volitional exhaustion or until the participant is unable to maintain the required running pace according to the test protocol. The Yo-Yo IR1 is used to induce acute physiological stress for the assessment of metabolic, inflammatory, and fatigue-related responses.

Study summary

This study aims to evaluate the effects of interval exercise on metabolic and inflammatory responses, energy substrate utilization, and fatigue in trained female basketball players. High-intensity intermittent exercise is a key component of basketball performance and induces substantial metabolic and physiological stress. However, the acute relationships between exercise-induced metabolic changes, inflammatory responses, substrate utilization, and fatigue in female basketball players remain insufficiently understood.

In this prospective interventional study, eligible female basketball players will complete a standardized interval exercise protocol designed to replicate the physiological demands of competitive basketball. Physiological, biochemical, and perceptual measurements will be collected before exercise, immediately after exercise, and during recovery. Primary outcomes include changes in metabolic and inflammatory biomarkers, energy substrate utilization, and fatigue-related responses. Secondary outcomes include selected physiological and performance-related variables associated with recovery from high-intensity interval exercise.

The findings of this study will improve the understanding of the physiological responses to interval exercise in female basketball players and may contribute to the development of evidence-based training and recovery strategies aimed at optimizing performance and athlete health.

Eligibility

Sex
FEMALE
Min age
16 Years
Max age
22 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Female, aged 16-22 years. * Regular participation in organized basketball training. * Current medical clearance for sports participation. * No contraindications to high-intensity physical exercise. * Willingness and ability to provide written informed consent (and parental/legal guardian consent where required for minors). * Willingness to comply with all study procedures. * Menstrual cycle phase will be recorded for all participants and considered as a potential covariate in the statistical analyses. Exclusion Criteria: * Current musculoskeletal injury or any condition preventing maximal exercise. * Metabolic, cardiovascular, inflammatory, or other chronic diseases affecting exercise capacity or study outcomes. * Current use of anti-inflammatory medications. * Use of supplements or substances that may influence the measured metabolic or inflammatory parameters. * Refusal to undergo blood sampling. * Failure to comply with pre-test instructions (e.g., dietary or exercise restrictions).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Poznań University of Physical Education, Faculty of Sport Sciences in Gorzów Wielkopolski, Poland; Department of Biological Sciences. Gorzów Wielkopolski Poland

More Poznan University of Physical Education trials in Poland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07752459 on ClinicalTrials.gov ↗ ← All trials in Poland